Business context and reporting period
Equillium, Inc. is a clinical-stage biotechnology company developing treatments for severe autoimmune and inflammatory diseases. This unaudited Form 10-Q covers the three months ended March 31, 2022; the comparable period is the three months ended March 31, 2021. The company had no product revenue and reported no revenue from its principal operations.
In February 2022, Equillium acquired Bioniz Therapeutics, adding clinical-stage candidates EQ101 and EQ102 and a discovery platform to its itolizumab (EQ001) pipeline.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $10.8 million | $5.9 million |
| Acquired in-process R&D expense | $23.0 million | None |
| General and administrative expense | $3.5 million | $2.8 million |
| Total operating expenses | $37.3 million | $8.7 million |
| Net loss | $37.4 million | $9.0 million |
| Net loss per share, basic and diluted | $1.17 | $0.33 |
| Net cash used in operating activities | $12.1 million | $7.9 million |
No meaningful operating margin comparison is available because the company had no revenue. The large year-over-year increase in loss primarily reflects the $23.0 million Bioniz acquired in-process R&D charge, which was expensed because the acquired candidates had no alternative future use.
At March 31, 2022, cash and cash equivalents were $26.2 million and short-term investments were $42.6 million, totaling $68.8 million, versus $80.7 million at December 31, 2021. Current assets were $72.1 million and current liabilities were $13.1 million, implying working capital of approximately $59.0 million. Cash and cash equivalents declined by $24.1 million during the quarter; the company also purchased short-term investments, so this cash decline should not be read as the change in total liquid resources.
Notes payable had a carrying amount of $10.2 million ($2.9 million current and $7.4 million long-term). The $10.0 million term loan matures June 1, 2024. Following achievement of the Phase 3 aGVHD milestone, interest-only payments extend through September 30, 2022, after which principal and interest payments resume. The company reported compliance with loan covenants at quarter-end. It used no cash in financing activities during Q1 2022; Q1 2021 included approximately $30.0 million of registered direct offering proceeds.
Material changes versus the prior comparable period
- R&D expense rose by $4.9 million, primarily from EQUATOR Phase 3 start-up costs, higher compensation and non-clinical research, and Bioniz transaction costs.
- Net loss increased by $28.4 million, largely due to the one-time $23.0 million acquired in-process R&D charge associated with Bioniz.
- Operating cash use rose by $4.2 million, which management attributed mainly to increased research and clinical development activity and headcount.
- The company issued 4,820,230 shares at closing for the Bioniz acquisition. Up to another 879,252 shares may be issued 18 months after closing, subject to transaction adjustments.
- Cash provided by financing was nil, compared with $30.0 million in Q1 2021 from the registered direct offering.
Outlook, commentary and key risks
- Management said available cash, cash equivalents and short-term investments were expected to fund operations for at least 12 months from the filing date. The company expects continued losses and increased spending as it advances its pipeline; it does not expect product-sales revenue within the next 12 months, if ever.
- Equillium initiated the pivotal Phase 3 EQUATOR study of itolizumab in aGVHD in March 2022. It planned to report interim lupus nephritis study data in mid-2022, initiate a Phase 2 EQ101 alopecia areata study in the second half of 2022, and initiate a Phase 1 EQ102 study in the second half of 2022.
- Itolizumab asthma development was deprioritized after the Phase 1b EQUIP study met its safety and tolerability objective; the company cited pandemic-related trial challenges and said it would reassess future asthma development.
- The Bioniz transaction included contingent payments of up to $57.5 million tied to regulatory events and up to $250 million tied to commercialization events for EQ101. These are contingent obligations, not current-period cash payments.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; dependence on external CROs and manufacturers, including Biocon in India for itolizumab; the need for future financing and potential shareholder dilution; and reliance on the Biocon license, which carries development obligations, milestones and royalties.
- Management cited COVID-19 and the conflict in Ukraine as sources of potential trial, supply-chain and capital-market disruption. It also disclosed that itolizumab is of Cuban origin and that its development relies on applicable U.S. sanctions authorizations.
- The company reported no legal proceedings and concluded disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2022.
Important facts for investors to verify
- Trial progress, enrollment, safety findings and data timing for EQUATOR, EQUALISE and the planned EQ101 and EQ102 studies.
- Whether the stated 12-month liquidity runway remains valid as development costs rise, and the timing and terms of any additional financing.
- The final number of Bioniz shares issued, any adjustments, and the probability and potential timing of contingent milestone payments.
- Term-loan repayment requirements after September 30, 2022, applicable interest rate, and continued covenant compliance.
- Continued access to itolizumab supply and the status of the Biocon license, relevant regulatory permissions and any manufacturing or export constraints.